US 11,813,232 B2
Analogs of deutetrabenazine, their preparation and use
Chengzhi Zhang, San Diego, CA (US); and James Kerr, North Wales, PA (US)
Assigned to Auspex Pharmaceuticals, Inc., Parsippany, NJ (US)
Filed by AUSPEX PHARMACEUTICALS, INC., Parsippany, NJ (US)
Filed on Mar. 15, 2018, as Appl. No. 15/922,329.
Claims priority of provisional application 62/471,484, filed on Mar. 15, 2017.
Prior Publication US 2018/0263972 A1, Sep. 20, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4745 (2006.01); A61P 25/14 (2006.01); A61P 25/28 (2006.01); C07D 471/04 (2006.01); A61K 31/473 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 31/473 (2013.01); A61P 25/14 (2018.01); A61P 25/28 (2018.01); C07D 471/04 (2013.01)] 7 Claims
 
1. A process for preparing a deutetrabenazine drug product in the form of a tablet, that has no more than 0.4 area-% of Compound 2 relative to the concentration of deutetrabenazine in the drug product after storage at room temperature for one month, comprising:
obtaining a deutetrabenazine drug substance comprising Compound 2 in an amount that is not more than 0.15 area-%, relative to the concentration of the deutetrabenazine in the deutetrabenazine drug substance;

OG Complex Work Unit Chemistry
wherein the amount of Compound 2 is determined by an HPLC method comprising a C18, 150×4.6 mm, 3.5 μm column and a photodiode array/ultraviolet detector at 220 nm; and
admixing the deutetrabenazine drug substance with an excipient to produce the deutetrabenazine drug product in the form of a tablet;
wherein the deutetrabenazine drug product has no more than 0.4 area-% of Compound 2, relative to the concentration of deutetrabenazine in the drug product, based on a determination by the HPLC method, after the storage at room temperature for one month.